Spagnol, G.; Sensi, F.; De Tommasi, O.; Marchetti, M.; Bonaldo, G.; Xhindoli, L.; Noventa, M.; Agostini, M.; Tozzi, R.; Saccardi, C.
Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine. Cancers 2023, 15, 2059.
https://doi.org/10.3390/cancers15072059
AMA Style
Spagnol G, Sensi F, De Tommasi O, Marchetti M, Bonaldo G, Xhindoli L, Noventa M, Agostini M, Tozzi R, Saccardi C.
Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine. Cancers. 2023; 15(7):2059.
https://doi.org/10.3390/cancers15072059
Chicago/Turabian Style
Spagnol, Giulia, Francesca Sensi, Orazio De Tommasi, Matteo Marchetti, Giulio Bonaldo, Livia Xhindoli, Marco Noventa, Marco Agostini, Roberto Tozzi, and Carlo Saccardi.
2023. "Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine" Cancers 15, no. 7: 2059.
https://doi.org/10.3390/cancers15072059
APA Style
Spagnol, G., Sensi, F., De Tommasi, O., Marchetti, M., Bonaldo, G., Xhindoli, L., Noventa, M., Agostini, M., Tozzi, R., & Saccardi, C.
(2023). Patient Derived Organoids (PDOs), Extracellular Matrix (ECM), Tumor Microenvironment (TME) and Drug Screening: State of the Art and Clinical Implications of Ovarian Cancer Organoids in the Era of Precision Medicine. Cancers, 15(7), 2059.
https://doi.org/10.3390/cancers15072059
